Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 293

1.

Bone morphogenetic protein-6 inhibits fibrogenesis in scleroderma offering new treatment options of fibrotic skin disease.

Arndt S, Karrer S, Hellerbrand C, Bosserhoff AK.

J Invest Dermatol. 2019 Mar 13. pii: S0022-202X(19)31315-6. doi: 10.1016/j.jid.2019.02.020. [Epub ahead of print]

PMID:
30878675
2.

Phototherapy-induced elevation of serum level of melanoma inhibitory activity.

Datz E, Zeman F, Koller M, Szeimies RM, Berneburg M, Landthaler M, Bosserhoff AK, Karrer S.

Photodermatol Photoimmunol Photomed. 2019 Feb 28. doi: 10.1111/phpp.12461. [Epub ahead of print]

PMID:
30815924
3.

Neuroblastoma RAS Viral Oncogene Homolog (NRAS) Is a Novel Prognostic Marker and Contributes to Sorafenib Resistance in Hepatocellular Carcinoma.

Dietrich P, Gaza A, Wormser L, Fritz V, Hellerbrand C, Bosserhoff AK.

Neoplasia. 2019 Mar;21(3):257-268. doi: 10.1016/j.neo.2018.11.011. Epub 2019 Jan 25.

4.

The myelin protein PMP2 is regulated by SOX10 and drives melanoma cell invasion.

Graf SA, Heppt MV, Wessely A, Krebs S, Kammerbauer C, Hornig E, Strieder A, Blum H, Bosserhoff AK, Berking C.

Pigment Cell Melanoma Res. 2018 Dec 2. doi: 10.1111/pcmr.12760. [Epub ahead of print]

PMID:
30506895
5.

Encapsulation of Rat Bone Marrow Derived Mesenchymal Stem Cells in Alginate Dialdehyde/Gelatin Microbeads with and without Nanoscaled Bioactive Glass for In Vivo Bone Tissue Engineering.

Rottensteiner-Brandl U, Detsch R, Sarker B, Lingens L, Köhn K, Kneser U, Bosserhoff AK, Horch RE, Boccaccini AR, Arkudas A.

Materials (Basel). 2018 Oct 1;11(10). pii: E1880. doi: 10.3390/ma11101880.

6.

BMP6-induced modulation of the tumor micro-milieu.

Stieglitz D, Lamm S, Braig S, Feuerer L, Kuphal S, Dietrich P, Arndt S, Echtenacher B, Hellerbrand C, Karrer S, Bosserhoff AK.

Oncogene. 2019 Jan;38(5):609-621. doi: 10.1038/s41388-018-0475-x. Epub 2018 Aug 31.

PMID:
30171260
7.

Cold atmospheric plasma causes a calcium influx in melanoma cells triggering CAP-induced senescence.

Schneider C, Gebhardt L, Arndt S, Karrer S, Zimmermann JL, Fischer MJM, Bosserhoff AK.

Sci Rep. 2018 Jul 3;8(1):10048. doi: 10.1038/s41598-018-28443-5.

8.

Cold atmospheric plasma treatment inhibits growth in colorectal cancer cells.

Schneider C, Arndt S, Zimmermann JL, Li Y, Karrer S, Bosserhoff AK.

Biol Chem. 2018 Dec 19;400(1):111-122. doi: 10.1515/hsz-2018-0193.

PMID:
29908123
9.

The importance of melanoma inhibitory activity gene family in the tumor progression of oral cancer.

Sasahira T, Bosserhoff AK, Kirita T.

Pathol Int. 2018 May;68(5):278-286. doi: 10.1111/pin.12672. Epub 2018 Apr 14. Review.

PMID:
29655307
10.

Selenium-binding protein 1 is down-regulated in malignant melanoma.

Schott M, de Jel MM, Engelmann JC, Renner P, Geissler EK, Bosserhoff AK, Kuphal S.

Oncotarget. 2018 Jan 2;9(12):10445-10456. doi: 10.18632/oncotarget.23853. eCollection 2018 Feb 13.

11.

MicroRNA-622 is a novel mediator of tumorigenicity in melanoma by targeting Kirsten rat sarcoma.

Dietrich P, Kuphal S, Spruss T, Hellerbrand C, Bosserhoff AK.

Pigment Cell Melanoma Res. 2018 Sep;31(5):614-629. doi: 10.1111/pcmr.12698. Epub 2018 Mar 25.

PMID:
29495114
12.

Combined effects of PLK1 and RAS in hepatocellular carcinoma reveal rigosertib as promising novel therapeutic "dual-hit" option.

Dietrich P, Freese K, Mahli A, Thasler WE, Hellerbrand C, Bosserhoff AK.

Oncotarget. 2017 Dec 11;9(3):3605-3618. doi: 10.18632/oncotarget.23188. eCollection 2018 Jan 9.

13.

UVB radiation represses CYLD expression in melanocytes.

Kuphal S, Schneider N, Massoumi R, Hellerbrand C, Bosserhoff AK.

Oncol Lett. 2017 Dec;14(6):7262-7268. doi: 10.3892/ol.2017.7120. Epub 2017 Oct 3.

14.

Wild type Kirsten rat sarcoma is a novel microRNA-622-regulated therapeutic target for hepatocellular carcinoma and contributes to sorafenib resistance.

Dietrich P, Koch A, Fritz V, Hartmann A, Bosserhoff AK, Hellerbrand C.

Gut. 2018 Jul;67(7):1328-1341. doi: 10.1136/gutjnl-2017-315402. Epub 2017 Dec 23.

PMID:
29275358
15.

Cold atmospheric plasma (CAP) activates angiogenesis-related molecules in skin keratinocytes, fibroblasts and endothelial cells and improves wound angiogenesis in an autocrine and paracrine mode.

Arndt S, Unger P, Berneburg M, Bosserhoff AK, Karrer S.

J Dermatol Sci. 2018 Feb;89(2):181-190. doi: 10.1016/j.jdermsci.2017.11.008. Epub 2017 Nov 26.

PMID:
29191392
16.

Immunometabolic Determinants of Chemoradiotherapy Response and Survival in Head and Neck Squamous Cell Carcinoma.

Krupar R, Hautmann MG, Pathak RR, Varier I, McLaren C, Gaag D, Hellerbrand C, Evert M, Laban S, Idel C, Sandulache V, Perner S, Bosserhoff AK, Sikora AG.

Am J Pathol. 2018 Jan;188(1):72-83. doi: 10.1016/j.ajpath.2017.09.013. Epub 2017 Oct 27.

PMID:
29107073
17.

Wild-type KRAS is a novel therapeutic target for melanoma contributing to primary and acquired resistance to BRAF inhibition.

Dietrich P, Kuphal S, Spruss T, Hellerbrand C, Bosserhoff AK.

Oncogene. 2018 Feb 15;37(7):897-911. doi: 10.1038/onc.2017.391. Epub 2017 Oct 23.

PMID:
29059159
18.

Melanoma sponge on pigmentation gene to reduce tumour-suppressive microRNAs.

Dietrich P, Bosserhoff AK.

Pigment Cell Melanoma Res. 2018 May;31(3):350-351. doi: 10.1111/pcmr.12660. Epub 2017 Nov 2. No abstract available.

PMID:
29049866
19.

Comparison of the Serum Tumor Markers S100 and Melanoma-inhibitory Activity (MIA) in the Monitoring of Patients with Metastatic Melanoma Receiving Vaccination Immunotherapy with Dendritic Cells.

Uslu U, Schliep S, Schliep K, Erdmann M, Koch HU, Parsch H, Rosenheinrich S, Anzengruber D, Bosserhoff AK, Schuler G, Schuler-Thurner B.

Anticancer Res. 2017 Sep;37(9):5033-5037.

PMID:
28870930
20.

Investigation of toxicity and mutagenicity of cold atmospheric argon plasma.

Maisch T, Bosserhoff AK, Unger P, Heider J, Shimizu T, Zimmermann JL, Morfill GE, Landthaler M, Karrer S.

Environ Mol Mutagen. 2017 Apr;58(3):172-177. doi: 10.1002/em.22086.

PMID:
28370324

Supplemental Content

Loading ...
Support Center